-
1
-
-
18144364350
-
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
-
Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R and Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005; 16:159-178.
-
(2005)
Cytokine Growth Factor Rev.
, vol.16
, pp. 159-178
-
-
Presta, M.1
Dell'Era, P.2
Mitola, S.3
Moroni, E.4
Ronca, R.5
Rusnati, M.6
-
2
-
-
0026738943
-
Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells
-
Tanaka A, Miyamoto K, Minamino N, Takeda M, Sato B, Matsuo H and Matsumoto K. Cloning and characterization of an androgen-induced growth factor essential for the androgen-dependent growth of mouse mammary carcinoma cells. Proc Natl Acad Sci U S A. 1992; 89:8928-8932.
-
(1992)
Proc Natl Acad Sci U S A.
, vol.89
, pp. 8928-8932
-
-
Tanaka, A.1
Miyamoto, K.2
Minamino, N.3
Takeda, M.4
Sato, B.5
Matsuo, H.6
Matsumoto, K.7
-
4
-
-
34249990979
-
Role of fibroblast growth factor 8 in growth and progression of hormonal cancer
-
Mattila MM and Harkonen PL. Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. Cytokine Growth Factor Rev. 2007; 18:257-266.
-
(2007)
Cytokine Growth Factor Rev.
, vol.18
, pp. 257-266
-
-
Mattila, M.M.1
Harkonen, P.L.2
-
5
-
-
0034547972
-
The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells
-
Song Z, Powell WC, Kasahara N, van Bokhoven A, Miller GJ and Roy-Burman P. The effect of fibroblast growth factor 8, isoform b, on the biology of prostate carcinoma cells and their interaction with stromal cells. Cancer Res. 2000; 60:6730-6736.
-
(2000)
Cancer Res.
, vol.60
, pp. 6730-6736
-
-
Song, Z.1
Powell, W.C.2
Kasahara, N.3
van Bokhoven, A.4
Miller, G.J.5
Roy-Burman, P.6
-
6
-
-
34748912386
-
Androgen-response elements in hormone-refractory prostate cancer:implications for treatment development
-
Hsieh AC, Small EJ and Ryan CJ. Androgen-response elements in hormone-refractory prostate cancer:implications for treatment development. The Lancet Oncology. 2007; 8:933-939.
-
(2007)
The Lancet Oncology.
, vol.8
, pp. 933-939
-
-
Hsieh, A.C.1
Small, E.J.2
Ryan, C.J.3
-
7
-
-
0029831216
-
Molecular cloning and characterization of human FGF8 alternative messenger RNA forms
-
Ghosh AK, Shankar DB, Shackleford GM, Wu K, T'Ang A, Miller GJ, Zheng J and Roy-Burman P. Molecular cloning and characterization of human FGF8 alternative messenger RNA forms. Cell Growth Differ. 1996; 7:1425-1434.
-
(1996)
Cell Growth Differ.
, vol.7
, pp. 1425-1434
-
-
Ghosh, A.K.1
Shankar, D.B.2
Shackleford, G.M.3
Wu, K.4
T'Ang, A.5
Miller, G.J.6
Zheng, J.7
Roy-Burman, P.8
-
8
-
-
70249146546
-
Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands
-
Schwertfeger KL. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets. 2009; 10:632-644.
-
(2009)
Curr Drug Targets.
, vol.10
, pp. 632-644
-
-
Schwertfeger, K.L.1
-
9
-
-
43949123830
-
FGF-8 is involved in bone metastasis of prostate cancer
-
Valta MP, Tuomela J, Bjartell A, Valve E, Vaananen HK and Harkonen P. FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer. 2008; 123:22-31.
-
(2008)
Int J Cancer.
, vol.123
, pp. 22-31
-
-
Valta, M.P.1
Tuomela, J.2
Bjartell, A.3
Valve, E.4
Vaananen, H.K.5
Harkonen, P.6
-
10
-
-
0036733760
-
Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia
-
Song Z, Wu X, Powell WC, Cardiff RD, Cohen MB, Tin RT, Matusik RJ, Miller GJ and Roy-Burman P. Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. Cancer Res. 2002; 62:5096-5105.
-
(2002)
Cancer Res.
, vol.62
, pp. 5096-5105
-
-
Song, Z.1
Wu, X.2
Powell, W.C.3
Cardiff, R.D.4
Cohen, M.B.5
Tin, R.T.6
Matusik, R.J.7
Miller, G.J.8
Roy-Burman, P.9
-
11
-
-
0032546230
-
Downregulation of human FGF8 activity by antisense constructs in murine fibroblastic and human prostatic carcinoma cell systems
-
Rudra-Ganguly N, Zheng J, Hoang AT and Roy-Burman P. Downregulation of human FGF8 activity by antisense constructs in murine fibroblastic and human prostatic carcinoma cell systems. Oncogene. 1998; 16:1487-1492.
-
(1998)
Oncogene.
, vol.16
, pp. 1487-1492
-
-
Rudra-Ganguly, N.1
Zheng, J.2
Hoang, A.T.3
Roy-Burman, P.4
-
12
-
-
17644423119
-
Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility
-
Garlanda C, Bottazzi B, Bastone A and Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005; 23:337-366.
-
(2005)
Annu Rev Immunol.
, vol.23
, pp. 337-366
-
-
Garlanda, C.1
Bottazzi, B.2
Bastone, A.3
Mantovani, A.4
-
13
-
-
2542604364
-
Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis
-
Rusnati M, Camozzi M, Moroni E, Bottazzi B, Peri G, Indraccolo S, Amadori A, Mantovani A and Presta M. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood. 2004; 104:92-99.
-
(2004)
Blood.
, vol.104
, pp. 92-99
-
-
Rusnati, M.1
Camozzi, M.2
Moroni, E.3
Bottazzi, B.4
Peri, G.5
Indraccolo, S.6
Amadori, A.7
Mantovani, A.8
Presta, M.9
-
14
-
-
33747336999
-
Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3
-
Camozzi M, Rusnati M, Bugatti A, Bottazzi B, Mantovani A, Bastone A, Inforzato A, Vincenti S, Bracci L, Mastroianni D and Presta M. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem. 2006; 281:22605-22613.
-
(2006)
J Biol Chem.
, vol.281
, pp. 22605-22613
-
-
Camozzi, M.1
Rusnati, M.2
Bugatti, A.3
Bottazzi, B.4
Mantovani, A.5
Bastone, A.6
Inforzato, A.7
Vincenti, S.8
Bracci, L.9
Mastroianni, D.10
Presta, M.11
-
15
-
-
84877745098
-
Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer
-
Ronca R, Alessi P, Coltrini D, Di Salle E, Giacomini A, Leali D, Corsini M, Belleri M, Tobia C, Garlanda C, Bonomi E, Tardanico R, Vermi W and Presta M. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer. J Pathol. 2013; 230:228-238.
-
(2013)
J Pathol.
, vol.230
, pp. 228-238
-
-
Ronca, R.1
Alessi, P.2
Coltrini, D.3
Di Salle, E.4
Giacomini, A.5
Leali, D.6
Corsini, M.7
Belleri, M.8
Tobia, C.9
Garlanda, C.10
Bonomi, E.11
Tardanico, R.12
Vermi, W.13
Presta, M.14
-
16
-
-
80052761943
-
Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors
-
Leali D, Alessi P, Coltrini D, Ronca R, Corsini M, Nardo G, Indraccolo S and Presta M. Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors. Mol Cancer Ther. 2011; 10:1600-1610.
-
(2011)
Mol Cancer Ther.
, vol.10
, pp. 1600-1610
-
-
Leali, D.1
Alessi, P.2
Coltrini, D.3
Ronca, R.4
Corsini, M.5
Nardo, G.6
Indraccolo, S.7
Presta, M.8
-
17
-
-
34548189432
-
Role of the soluble pattern recognition receptor PTX3 in vascular biology
-
Presta M, Camozzi M, Salvatori G and Rusnati M. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med. 2007; 11:723-738.
-
(2007)
J Cell Mol Med.
, vol.11
, pp. 723-738
-
-
Presta, M.1
Camozzi, M.2
Salvatori, G.3
Rusnati, M.4
-
18
-
-
84890498808
-
Long Pentraxin-3 Inhibits Epithelial-Mesenchymal Transition in Melanoma Cells
-
Ronca R, Di Salle E, Giacomini A, Leali D, Alessi P, Coltrini D, Ravelli C, Matarazzo S, Ribatti D, Vermi W and Presta M. Long Pentraxin-3 Inhibits Epithelial-Mesenchymal Transition in Melanoma Cells. Mol Cancer Ther. 2013; 12:2760-2771.
-
(2013)
Mol Cancer Ther.
, vol.12
, pp. 2760-2771
-
-
Ronca, R.1
Di Salle, E.2
Giacomini, A.3
Leali, D.4
Alessi, P.5
Coltrini, D.6
Ravelli, C.7
Matarazzo, S.8
Ribatti, D.9
Vermi, W.10
Presta, M.11
-
19
-
-
77952901564
-
The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2
-
Inforzato A, Baldock C, Jowitt TA, Holmes DF, Lindstedt R, Marcellini M, Rivieccio V, Briggs DC, Kadler KE, Verdoliva A, Bottazzi B, Mantovani A, Salvatori G and Day AJ. The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2. J Biol Chem. 2010; 285:17681-17692.
-
(2010)
J Biol Chem.
, vol.285
, pp. 17681-17692
-
-
Inforzato, A.1
Baldock, C.2
Jowitt, T.A.3
Holmes, D.F.4
Lindstedt, R.5
Marcellini, M.6
Rivieccio, V.7
Briggs, D.C.8
Kadler, K.E.9
Verdoliva, A.10
Bottazzi, B.11
Mantovani, A.12
Salvatori, G.13
Day, A.J.14
-
20
-
-
77957117187
-
Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide
-
Leali D, Bianchi R, Bugatti A, Nicoli S, Mitola S, Ragona L, Tomaselli S, Gallo G, Catello S, Rivieccio V, Zetta L and Presta M. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide. J Cell Mol Med. 2010; 14:2109-2121.
-
(2010)
J Cell Mol Med.
, vol.14
, pp. 2109-2121
-
-
Leali, D.1
Bianchi, R.2
Bugatti, A.3
Nicoli, S.4
Mitola, S.5
Ragona, L.6
Tomaselli, S.7
Gallo, G.8
Catello, S.9
Rivieccio, V.10
Zetta, L.11
Presta, M.12
-
21
-
-
0035901963
-
FGF-8b increases angiogenic capacity and tumor growth of androgenregulated S115 breast cancer cells
-
Mattila MM, Ruohola JK, Valve EM, Tasanen MJ, Seppanen JA and Harkonen PL. FGF-8b increases angiogenic capacity and tumor growth of androgenregulated S115 breast cancer cells. Oncogene. 2001; 20:2791-2804.
-
(2001)
Oncogene.
, vol.20
, pp. 2791-2804
-
-
Mattila, M.M.1
Ruohola, J.K.2
Valve, E.M.3
Tasanen, M.J.4
Seppanen, J.A.5
Harkonen, P.L.6
-
22
-
-
0028911462
-
Prostate cancer in a transgenic mouse
-
Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ and Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A. 1995; 92:3439-3443.
-
(1995)
Proc Natl Acad Sci U S A.
, vol.92
, pp. 3439-3443
-
-
Greenberg, N.M.1
DeMayo, F.2
Finegold, M.J.3
Medina, D.4
Tilley, W.D.5
Aspinall, J.O.6
Cunha, G.R.7
Donjacour, A.A.8
Matusik, R.J.9
Rosen, J.M.10
-
23
-
-
0033635299
-
Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization
-
Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ and Mohammadi M. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell. 2000; 6:743-750.
-
(2000)
Mol Cell.
, vol.6
, pp. 743-750
-
-
Schlessinger, J.1
Plotnikov, A.N.2
Ibrahimi, O.A.3
Eliseenkova, A.V.4
Yeh, B.K.5
Yayon, A.6
Linhardt, R.J.7
Mohammadi, M.8
-
24
-
-
34250640742
-
The gelatin sponge-chorioallantoic membrane assay
-
Ribatti D, Nico B, Vacca A and Presta M. The gelatin sponge-chorioallantoic membrane assay. Nat Protoc. 2006; 1:85-91.
-
(2006)
Nat Protoc.
, vol.1
, pp. 85-91
-
-
Ribatti, D.1
Nico, B.2
Vacca, A.3
Presta, M.4
-
25
-
-
0033611570
-
Increased expression of fibroblast growth factor 8 in human breast cancer
-
Marsh SK, Bansal GS, Zammit C, Barnard R, Coope R, Roberts-Clarke D, Gomm JJ, Coombes RC and Johnston CL. Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene. 1999; 18:1053-1060.
-
(1999)
Oncogene.
, vol.18
, pp. 1053-1060
-
-
Marsh, S.K.1
Bansal, G.S.2
Zammit, C.3
Barnard, R.4
Coope, R.5
Roberts-Clarke, D.6
Gomm, J.J.7
Coombes, R.C.8
Johnston, C.L.9
-
26
-
-
0033614366
-
FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease
-
Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE and Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene. 1999; 18:2755-2761.
-
(1999)
Oncogene.
, vol.18
, pp. 2755-2761
-
-
Dorkin, T.J.1
Robinson, M.C.2
Marsh, C.3
Bjartell, A.4
Neal, D.E.5
Leung, H.Y.6
-
27
-
-
42949151299
-
A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows antitumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions
-
Maruyama-Takahashi K, Shimada N, Imada T, Maekawa-Tokuda Y, Ishii T, Ouchi J, Kusaka H, Miyaji H, Akinaga S, Tanaka A and Shitara K. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows antitumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions. Prostate. 2008; 68:640-650.
-
(2008)
Prostate.
, vol.68
, pp. 640-650
-
-
Maruyama-Takahashi, K.1
Shimada, N.2
Imada, T.3
Maekawa-Tokuda, Y.4
Ishii, T.5
Ouchi, J.6
Kusaka, H.7
Miyaji, H.8
Akinaga, S.9
Tanaka, A.10
Shitara, K.11
-
28
-
-
33845331706
-
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas
-
Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T, Iravani M, Fenwick K, Weber B, Hardisson D, Schmitt FC, Palacios J, et al. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res. 2006; 12:6652-6662.
-
(2006)
Clin Cancer Res.
, vol.12
, pp. 6652-6662
-
-
Reis-Filho, J.S.1
Simpson, P.T.2
Turner, N.C.3
Lambros, M.B.4
Jones, C.5
Mackay, A.6
Grigoriadis, A.7
Sarrio, D.8
Savage, K.9
Dexter, T.10
Iravani, M.11
Fenwick, K.12
Weber, B.13
Hardisson, D.14
Schmitt, F.C.15
Palacios, J.16
-
29
-
-
14844307601
-
Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer
-
Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN and Leung HY. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer. 2005; 92:320-327.
-
(2005)
Br J Cancer.
, vol.92
, pp. 320-327
-
-
Gowardhan, B.1
Douglas, D.A.2
Mathers, M.E.3
McKie, A.B.4
McCracken, S.R.5
Robson, C.N.6
Leung, H.Y.7
-
30
-
-
22244492038
-
Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor
-
Brown AP, Courtney CL, King LM, Groom SC and Graziano MJ. Cartilage dysplasia and tissue mineralization in the rat following administration of a FGF receptor tyrosine kinase inhibitor. Toxicol Pathol. 2005; 33:449-455.
-
(2005)
Toxicol Pathol.
, vol.33
, pp. 449-455
-
-
Brown, A.P.1
Courtney, C.L.2
King, L.M.3
Groom, S.C.4
Graziano, M.J.5
-
31
-
-
72249111162
-
Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: longpentraxin 3 as a novel antiangiogenic FGF2-antagonist
-
Alessi P, Leali D, Camozzi M, Cantelmo A, Albini A and Presta M. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: longpentraxin 3 as a novel antiangiogenic FGF2-antagonist. Eur Cytokine Netw. 2009; 20:225-234.
-
(2009)
Eur Cytokine Netw.
, vol.20
, pp. 225-234
-
-
Alessi, P.1
Leali, D.2
Camozzi, M.3
Cantelmo, A.4
Albini, A.5
Presta, M.6
-
32
-
-
26644471951
-
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
-
Casanovas O, Hicklin DJ, Bergers G and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005; 8:299-309.
-
(2005)
Cancer Cell.
, vol.8
, pp. 299-309
-
-
Casanovas, O.1
Hicklin, D.J.2
Bergers, G.3
Hanahan, D.4
-
33
-
-
67449132021
-
How well do angiogenesis inhibitors work? Biomarkers of response prove elusive
-
Brower V. How well do angiogenesis inhibitors work? Biomarkers of response prove elusive. J Natl Cancer Inst. 2009; 101:846-847.
-
(2009)
J Natl Cancer Inst.
, vol.101
, pp. 846-847
-
-
Brower, V.1
-
34
-
-
0034640103
-
Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity
-
Plotnikov AN, Hubbard SR, Schlessinger J and Mohammadi M. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell. 2000; 101:413-424.
-
(2000)
Cell.
, vol.101
, pp. 413-424
-
-
Plotnikov, A.N.1
Hubbard, S.R.2
Schlessinger, J.3
Mohammadi, M.4
-
35
-
-
30944448671
-
Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain
-
Olsen SK, Li JY, Bromleigh C, Eliseenkova AV, Ibrahimi OA, Lao Z, Zhang F, Linhardt RJ, Joyner AL and Mohammadi M. Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev. 2006; 20:185-198.
-
(2006)
Genes Dev.
, vol.20
, pp. 185-198
-
-
Olsen, S.K.1
Li, J.Y.2
Bromleigh, C.3
Eliseenkova, A.V.4
Ibrahimi, O.A.5
Lao, Z.6
Zhang, F.7
Linhardt, R.J.8
Joyner, A.L.9
Mohammadi, M.10
-
36
-
-
79959713140
-
Fibroblast growth factors and their receptors in cancer
-
Wesche J, Haglund K and Haugsten EM. Fibroblast growth factors and their receptors in cancer. Biochem J. 2011; 437:199-213.
-
(2011)
Biochem J.
, vol.437
, pp. 199-213
-
-
Wesche, J.1
Haglund, K.2
Haugsten, E.M.3
-
37
-
-
69249216604
-
The role of fibroblast growth factors in tumor growth
-
Korc M and Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Drug Targets. 2009; 9:639-651.
-
(2009)
Curr Drug Targets.
, vol.9
, pp. 639-651
-
-
Korc, M.1
Friesel, R.E.2
-
38
-
-
80053493427
-
Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis
-
Lieu C, Heymach J, Overman M, Tran H and Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011; 17:6130-6139.
-
(2011)
Clin Cancer Res.
, vol.17
, pp. 6130-6139
-
-
Lieu, C.1
Heymach, J.2
Overman, M.3
Tran, H.4
Kopetz, S.5
-
39
-
-
84859415553
-
Molecular pathways:fibroblast growth factor signaling: a new therapeutic opportunity in cancer
-
Brooks AN, Kilgour E and Smith PD. Molecular pathways:fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012; 18:1855-1862.
-
(2012)
Clin Cancer Res.
, vol.18
, pp. 1855-1862
-
-
Brooks, A.N.1
Kilgour, E.2
Smith, P.D.3
-
40
-
-
61649100307
-
The FGF family: biology, pathophysiology and therapy
-
Beenken A and Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov. 2009; 8:235-253.
-
(2009)
Nat Rev Drug Discov.
, vol.8
, pp. 235-253
-
-
Beenken, A.1
Mohammadi, M.2
-
41
-
-
79958247193
-
Targeting fibroblast-growth-factorreceptor- dependent signaling for cancer therapy
-
Heinzle C, Sutterluty H, Grusch M, Grasl-Kraupp B, Berger W and Marian B. Targeting fibroblast-growth-factorreceptor- dependent signaling for cancer therapy. Expert Opin Ther Targets. 2011; 15:829-846.
-
(2011)
Expert Opin Ther Targets.
, vol.15
, pp. 829-846
-
-
Heinzle, C.1
Sutterluty, H.2
Grusch, M.3
Grasl-Kraupp, B.4
Berger, W.5
Marian, B.6
-
42
-
-
75149170979
-
Fibroblast growth factor signalling:from development to cancer
-
Turner N and Grose R. Fibroblast growth factor signalling:from development to cancer. Nat Rev Cancer. 2010; 10:116-129.
-
(2010)
Nat Rev Cancer.
, vol.10
, pp. 116-129
-
-
Turner, N.1
Grose, R.2
-
43
-
-
77950551541
-
Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds
-
Colombo G, Margosio B, Ragona L, Neves M, Bonifacio S, Annis DS, Stravalaci M, Tomaselli S, Giavazzi R, Rusnati M, Presta M, Zetta L, Mosher DF, Ribatti D, Gobbi M and Taraboletti G. Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem. 2010; 285:8733-8742.
-
(2010)
J Biol Chem.
, vol.285
, pp. 8733-8742
-
-
Colombo, G.1
Margosio, B.2
Ragona, L.3
Neves, M.4
Bonifacio, S.5
Annis, D.S.6
Stravalaci, M.7
Tomaselli, S.8
Giavazzi, R.9
Rusnati, M.10
Presta, M.11
Zetta, L.12
Mosher, D.F.13
Ribatti, D.14
Gobbi, M.15
Taraboletti, G.16
-
44
-
-
78650481700
-
Antiangiogenic activity of a neutralizing human singlechain antibody fragment against fibroblast growth factor receptor 1
-
Ronca R, Benzoni P, Leali D, Urbinati C, Belleri M, Corsini M, Alessi P, Coltrini D, Calza S, Presta M and Dell'Era P. Antiangiogenic activity of a neutralizing human singlechain antibody fragment against fibroblast growth factor receptor 1. Mol Cancer Ther. 2010; 9:3244-3253.
-
(2010)
Mol Cancer Ther.
, vol.9
, pp. 3244-3253
-
-
Ronca, R.1
Benzoni, P.2
Leali, D.3
Urbinati, C.4
Belleri, M.5
Corsini, M.6
Alessi, P.7
Coltrini, D.8
Calza, S.9
Presta, M.10
Dell'Era, P.11
|